Prostaglandin analogues for ophthalmic use a review of comparative clinical effectiveness, cost-effectiveness, and guidelines
n 2015, CADTH prepared a Rapid Response Summary with Critical Appraisal on the clinical effectiveness and cost-effectiveness of BIM compared with other PGAs for ophthalmic use. The objective of the current report is to evaluate the evidence published as of 2015 on the clinical effectiveness and cost...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
Canadian Agency for Drugs and Technologies in Health
2020, February 18, 2020
|
| Edition: | Version: 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | n 2015, CADTH prepared a Rapid Response Summary with Critical Appraisal on the clinical effectiveness and cost-effectiveness of BIM compared with other PGAs for ophthalmic use. The objective of the current report is to evaluate the evidence published as of 2015 on the clinical effectiveness and cost-effectiveness of BIM versus other PGAs for ophthalmic use. Additionally, evidence-based guidelines regarding the use of BIM for elevated intraocular pressure will be reviewed |
|---|---|
| Physical Description: | 1 PDF file (46 pages) illustrations |